bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P4-12-06: Long-term follow-up of patients with invasive breast cancer treated with catheter-based accelerated partial breast irradiation following lumpectomy
Authors: Chen Cynthia , Do-Nguyen Chi Chi , Poole Lisa , Sizer Lina , Carter William B , Frazier Thomas G. 
Published: March 2020

Abstract
Introduction: A large number of breast cancer patients who are eligible for breast-conserving therapy (radiation following complete resection via lumpectomy) elect to undergo mastectomy to avoid radiation - with treatment length being the most significant deterrent. The development of accelerated partial breast irradiation (APBI) tailored treatment to target tissue at greatest risk of recurrence, balancing treatment-associated benefits with radiation exposure risk while shortening therapy duration from 6 weeks to 5 days. This study analyzed rates of ipsilateral breast tumor recurrence (IBTR) in patients with invasive breast cancer treated with resection followed by APBI delivered via catheter-based brachytherapy.
Methods: Retrospective data was collected on 406 patients with primary invasive breast cancer diagnosed from January 2007 to February 2014, treated with lumpectomy and adjuvant APBI catheter-based brachytherapy. Follow-up data was available for 390 patients (97.5%). Mean and median follow-up were 80.9 and 83.5 months respectively. 193 patients (49.4%) had at least 7 years of follow-up.
Results: 21 patients (5.4%) were found to have an IBTR. Of these patients, 14 (66.7%) experienced an IBTR in the same quadrant as their index cancer. 7 patients (33.3%) experienced an IBTR in a different quadrant. Only one patient (4.8%) experienced an IBTR within the first two years after conclusion of their primary treatment. Of the entire cohort, 7 patients (1.8%) were found to have a metastatic recurrence (one which occurred within the first two years after primary treatment) and 7 patients (1.8%) experienced new primary cancers diagnosed in their contralateral breasts.
Conclusion: The results of this investigation demonstrate catheter-based brachytherapy APBI delivered after breast-conserving surgery carries a relatively low risk for IBTR in patients with invasive breast cancer. We support its' use as an effective and valid alternative for selected early breast cancer patients desiring a significantly shorter, more convenient course of treatment in the adjuvant setting without increased risk of recurrence.
Citation Format: Cynthia Chen, Chi Chi Do-Nguyen, Lisa Poole, Lina Sizer, William B Carter, Thomas G. Frazier. Long-term follow-up of patients with invasive breast cancer treated with catheter-based accelerated partial breast irradiation following lumpectomy [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P4-12-06.
Abstract P4-12-08: Evaluation of acute toxicity in triple negative breast cancer patients receiving concurrent capecitabine and radiation
Authors: Modi Chirag , Yehia Zeinab Abou , Haffty Bruce 
Published: March 2020

Abstract
Purpose: The addition of capecitabine is shown to improve survival in patients with Triple Negative Breast Cancer (TNBC). Administration of adjuvant capecitabine and radiation therapy sequentially after surgery for TNBC patients prolongs the time from surgery to radiation treatment. The purpose of this study was to evaluate the rate of acute loco-regional toxicity in patients with triple negative breast cancer who received concurrent adjuvant capecitabine and radiation.
Materials and Methods: We performed a retrospective chart review of all patients diagnosed with breast cancer who were treated with capecitabine and radiation therapy at the Rutgers Cancer Institute of New Jersey between January 2010 and January 2019. Patients who had a previous radiation treatment course, hormone-receptor positive breast cancer and patients who received treatment sequentially were excluded. A total of 11 patients with TNBC who received concurrent capecitabine and RT were identified. Patient demographics, disease characteristics, radiation and capecitabine details, toxicity profile and treatment breaks were recorded. Toxicity was scored by the Common Terminology Criteria for Adverse Events version 5.
Results: Median age was 52 years [34- 65]. Median Follow up from last Radiation treatment was 12 months [1- 63]. All patients had locally advanced disease and were treated with neoadjuvant chemotherapy. Adjuvant capecitabine dose ranged between 1000-3000 mg daily concurrent with a definitive course of radiation treatment ranging between 45 Gy- 50.4 Gy followed by an additional 10-14 Gy boost. All patients received radiation to the elective regional lymph nodes. Grade 1 or 2 radiation dermatitis was seen in all patients (11/11). Of the 11 patients, 2 patients (18%) experienced Grade 3 radiation dermatitis within the treatment field. One of these patients had a one week treatment break in which capecitabine was withheld; she then continued to a reduced boost dose. The second patient had grade 3 moist desquamation after completion of her radiation dose. No grade 4 or 5 toxicities were reported. In 10/11 (91%) patients had grade 1 or 2 skin hyperpigmentation. In 2 of the 11 patients, capecitabine was held at one point during treatment.
Conclusion: Our study revealed an acceptable toxicity profile of receiving concurrent capecitabine and RT. These data support future prospective evaluation of this approach.
Citation Format: Chirag Modi, Zeinab Abou Yehia, Bruce Haffty. Evaluation of acute toxicity in triple negative breast cancer patients receiving concurrent capecitabine and radiation [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P4-12-08.
Abstract P4-12-12: Outcomes of exclusive radiation therapy for breast cancer in older women according to age and comorbidity status: An observational retrospective study
Authors: Waechter Lorraine , Cao Kim , Carton Matthieu , Kirova Youlia , Fourquet Alain 
Published: March 2020

Abstract
Introduction: This study aimed to assess the efficacy, tolerance and impact of comorbidities on outcomes in older women treated by exclusive radiation therapy (RT) for non-metastatic breast cancer (BC). Material and methods: We studied retrospectively female patients older 70 years at diagnosis, treated by exclusive RT for their BC between 2003 and 2013 in our Department. We analysed overall survival (OS), progression free survival (PFS), and specific survival (SS). Comorbidities were evaluated with the Charlson Comorbidity Index (CCI), and toxicities with the CCTCAE v3.0. Results: Between 2003 and 2013, there were 978 patients older than 70 treated for BC in our Hospital, and 817 received RT. Hypofractionated RT was delivered in 90.2% of patients. Of them, 66 patients underwent exclusive RT after refusal of surgery. The median age was 84.8 [71.3-91.7]. The median follow-up was 51.9 months [0.5- 99]. OS, SS and PFS at 5 years were 65.5% CI 95% [54.1-79.3], 86.3% CI 95% [77.2-96.4]), and 58.4% CI 95% [46.9-72.7], respectively. Five-year OS was statistically different according to age younger or older than 85 years: 72.9% CI 95% [58.4-91.1] and 57.1%, IC 95% [40.8-79.8], (p = 0.0026). Similar results were found for 5-year PFS: 64.5% CI 95% [49.5-84.1] and 51.6% CI 95% [35.8-74.5] (p = 0.014). The 5-year OS was also statistically different according to CCI score, respectively 70.8% CI 95% [57.0-87.9] and 59.8% CI 95 % [42.4-84.3] (p = 0.039) for a score of 0 or ≥ 1. Median CCI score was 1. There were 10.6% of the patients who experienced no toxicities; there were 59% who presented grade 1 and 2 radiodermatitis. Late toxicities were mainly fibrosis, observed in 39.4% of the patients, mostly of grade 1 and 2.Conclusion: Exclusive radiation therapy for non-metastatic BC in older women is feasible and well tolerated when adapted techniques are used, but the prognostic is strongly impacted by age and comorbidities.
Citation Format: Lorraine Waechter, Kim Cao, Matthieu Carton, Youlia Kirova, Alain Fourquet. Outcomes of exclusive radiation therapy for breast cancer in older women according to age and comorbidity status: An observational retrospective study [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P4-12-12.
Abstract P4-12-13: Correlation of radiotherapy with the prognosis of elderly patients with hormone receptor-positive breast cancer according to immunohistochemical subtyping
Authors: Zhang Jin 
Published: March 2020

Abstract
Objective:The present study examined the effect of radiotherapy on recurrence and survival in elderly patients with hormone-receptor-positive early breast cancer.
Methods:A retrospective analysis of 327 patients aged ≥65 years with stage I-II, hormone receptor positive breast cancer who underwent breast conserving surgery and received endocrine therapy (ET) or radiotherapy plus endocrine therapy (ET+RT) was performed. Both groups were divided into luminal A type and luminal B type subgroups. Evaluation criteria were 5-year disease free survival (DFS), local relapse rate (LRR), overall survival (OS), and distant metastasis rate (DMR).
Results:There were significant differences in 5-year DFS (HR 1.59, 95% CI 1.15-2.19, P=0.005) and LRR (HR 3.33, 95% CI 1.51-7.34, P=0.003), whereas there were no significant differences in OS and DMR between the two groups. In luminal A type, there was no significant difference in 5-year DFS, LRR, OS, and DMR between the ET group and the ET+RT group. In luminal B type, there were statistically significant differences in 5-year DFS (HR 2.188, 95% CI 1.37-3.49, P=0.001), LRR (HR 5.447, 95% CI 1.65-17.98, P=0.005), and OS (HR 1.752, 95% CI 1.01-3.054, P=0.048) between the two groups. In the ET group, there were significant differences between luminal A type and luminal B type in 5-year DFS (HR 1.841, 95% CI 1.23-2.75, P=0.003) and OS (HR 1.763, 95% CI 1.07-2.91, P=0.026).
Conclusions:After breast conserving surgery, radiotherapy can reduce the LRR and improve the DFS and OS of luminal B type elderly patients, whereas luminal A type elderly patients do not benefit from radiotherapy. Without radiotherapy, luminal A type patients have better DFS and OS than luminal B type patients.
Keywords: disease-free survival (DFS), distant metastasis rate (DMR), endocrine therapy, local relapse rate (LRR), overall survival (OS), radiotherapy
Citation Format: Jin Zhang. Correlation of radiotherapy with the prognosis of elderly patients with hormone receptor-positive breast cancer according to immunohistochemical subtyping [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P4-12-13.
Abstract P4-12-33: Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome
Authors: Le Anh N , Powers Jacquelyn , Zelley Kristin , Bradbury Angela , Shah Payal , Freedman Gary , Nathanson Katherine , Domchek Susan M , MacFarland Suzanne P , Maxwell Kara N 
Published: March 2020

Abstract
Background. Women with Li-Fraumeni syndrome (LFS), a cancer predisposition syndrome caused by germline mutations in TP53, have an over 50% risk of developing breast cancer (BC) by age 70. Providers often avoid adjuvant radiotherapy to treat BC in LFS patients due to a reported high risk of radiation-induced malignancies of over 30%. We aimed to investigate the characteristics of LFS-associated BC and the risk of subsequent malignancy in BC patients with LFS following adjuvant radiotherapy.
Methods. A single institution retrospective chart review was conducted for female BC patients with a confirmed germline TP53 mutation. Statistical analyses were performed to compare the frequency of radiation-induced malignancies in LFS patients to non-LFS BC cases reported in the Penn Medicine Cancer Registry (PMCR) (n=6607 patients total, 3863 who received radiation).
Results. Among 95 patients with LFS, we identified 51 female BC patients with 74 primary BC diagnoses. Of 51 patients, 57% had a history of BC only, and 25% had BC as their presenting diagnosis of LFS. LFS-associated BCs were predominantly invasive ductal carcinoma (48%) and HER2+ (58%). We analyzed 20 LFS BC patients who underwent adjuvant radiotherapy with an average follow up of 11.1 (2-20) years. Of 18 patients who received radiation in a curative setting, one (6%) patient developed thyroid cancer and one (6%) patient developed sarcoma in the radiation field. The incidence of thyroid cancer did not significantly differ between LFS-associated and non-LFS BCs. The incidence of radiation-induced sarcoma in patients with LFS is significantly higher than in non-LFS BC patients (0.03%, p=0.01).
Conclusion. We found a 6% (one in 18 patients) risk of radiation-induced sarcoma in LFS BC patients, lower than the previously reported rate of 33%. Adjuvant radiotherapy should be considered in LFS BC patients when the potential risk for locoregional recurrence (LRR) or the mortality benefit to radiation is greater than 6%.
Citation Format: Anh N Le, Jacquelyn Powers, Kristin Zelley, Angela Bradbury, Payal Shah, Gary Freedman, Katherine Nathanson, Susan M Domchek, Suzanne P MacFarland, Kara N Maxwell. Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P4-12-33.
Abstract P4-13-09: Oncoplastic breast conserving surgery (OBCS): A meta-analysis of real-world data
Authors: Kosasih Sebastian , Tayeh Salim , Mokbel Kefah , Kasem Abdul 
Published: March 2020

Abstract
Background: The role of oncoplastic breast conserving surgery (OBCS) is that of a middle ground between standard breast conserving surgery (SBCS) and mastectomy - it allows adequate resection margins of tumours unsuitable for traditional breast conserving surgery whilst allowing for a better cosmetic outcome and a reduced morbidity rate when compared to a traditional mastectomy. However, due to this being a relatively new type of procedure, there is limited evidence on its oncological safety, which is the ultimate goal of any breast cancer surgery.
Methods: This study aims to compare oncological safety of OBCS with SBCS and mastectomy by examining the relative risk of cancer recurrence and re-operation rates through meta-analysis. Literature search of Pubmed and Web of Science databases was conducted looking for studies up until February 2019. Meta-Analysis was performed using R Statistical Software (www.r-project.org).
Results: Initial finding of 645 studies was narrowed down to a pool of 19 studies including 18,163 patients. For the primary outcome measure of recurrence there was found to be no significant difference between the OBCS and SBCS or mastectomy (RR 0.861; 95% CI 0.640-1.160; p&lt;0.296). The secondary outcome measure of re-operation was initially found to be significant in favour of OBCS (RR 0.64; 95% CI 0.46-0.89; p&lt;0.01), however after adjustment for publication bias this was attenuated to an insignificant difference between the two study groups (RR 0.86; 95% CI 0.56-1.31; p&gt;0.05).
Conclusions: For both recurrence of cancer and re-operation rate, there was not found to be a significant difference between OBCS and more traditional techniques. This would suggest that OBCS is of comparable oncological safety to more established operations and a useful option in suitable patients.
Citation Format: Sebastian Kosasih, Salim Tayeh, Kefah Mokbel, Abdul Kasem. Oncoplastic breast conserving surgery (OBCS): A meta-analysis of real-world data [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P4-13-09.
Abstract P4-13-12: Impact of an image fusion technique for preoperative planning in breast conserving surgery in patients with non -mass enhancement on MRI
Authors: Nakano Shogo , Fujii Kimihito , Mouri Yukako , Kousaka Junko , Ando Takahito , Ido Mirai , Goto Manami , Ito Yukie , Banno Hirona , Suzuki Kenjiro 
Published: March 2020

Abstract
[Objective] The potential benefit of preoperative MRI is still being controversial and international guidelines do not recommend MRI for routine preoperative assessment. However, when breast conserving surgery (BCS) is considered for non-mass enhancement (NME), an area of enhancement without an associated space occupying mass or focus, biopsy-proven malignancy, the precise localization in surgical position is required. Although breast ultrasound (US) plays an adjunctive role in evaluation of MRI findings in preoperative planning for BCS, the US morphology least likely to have an US correlation was NME, not a mass enhancement or a focus, and the identification rate of NME in second look US was heterogeneous. Recently, real-time virtual sonography (RVS), which coordinates US with MRI that uses an image fusion technique by using magnet position tracking system, has been introduced in breast imaging. The purpose of this study was to evaluate the effect of preoperative planning using RVS on BCS in patients with NME. [Methods] We enrolled 12 consecutive patients who had lesions with NME that exceeded the US hypoechoic area, in which it was particularly difficult to evaluate the tumor margin. During preoperative planning before BCS, RVS was used to delineate the enhancing area on the breast surface after additional supine breast MRI was performed. We analyzed both the surgical margin positivity rate and the reoperation rate. [Results] The preoperative diagnosis by core needle biopsy were 7 DCIS and 5 invasive ductal carcinoma. NME distribution types were 5 segmental, 4 branching-ductal and 3 regional. The median diameters of the NME and hypo-echoic lesions were 24 mm (range: 12-39 mm) and 8.0 mm (range: 4.9-18 mm), respectively (p = 0.0002). After RVS-derived skin marking was performed on the surface of the affected breast, 7 lumpectomy and 5 quadrantectomy were conducted. The surgical margins were positive in 2 (17%) patients. The patients with positive margins were found to have ductal carcinoma in situ. None of the patients required additional resection. [Conclusion] Although further prospective studies are required, the findings of our preliminary study suggest that preoperative planning using RVS for BCS in patients with NME could improve both a surgical margin positive rate and a reoperation rate.
Citation Format: Shogo Nakano, Kimihito Fujii, Yukako Mouri, Junko Kousaka, Takahito Ando, Mirai Ido, Manami Goto, Yukie Ito, Hirona Banno, Kenjiro Suzuki. Impact of an image fusion technique for preoperative planning in breast conserving surgery in patients with non -mass enhancement on MRI [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P4-13-12.
Abstract P4-14-12: Effects of hepatitis C virus infection on the safety of chemotherapy for breast cancer patients: A retrospective chart analysis
Authors: Ghosh Saptaparni , Chen Minghua L , Weinberg Janice , Ko Naomi Y 
Published: March 2020

Abstract
Background: Hepatitis C virus (HCV) infection is a major health problem in the United States and breast cancer is the second most common cancer in US women. Despite these prevalent diseases, there is limited information available on the effects of a concurrent HCV infection among breast cancer patients receiving chemotherapy and the problems they face during their treatment. There are limited guidelines for chemotherapy treatment in HCV positive breast cancer patients. Methods: We performed a retrospective 2:1 matched case control analysis on breast cancer patients with a confirmed active HCV infection who received chemotherapy at Boston Medical Center between January 2000 and April 2015. Cases with HCV infection (n=6) were matched with controls (n=12) who were HCV negative. The controls were matched on age (decade) of diagnosis, stage of breast cancer, and intended chemotherapy regimen. We investigated dose delays, dose changes, hospitalization, hematologic reasons for dose delays, and variation in blood counts during the treatment period in these patients from their medical records. Statistical analysis was done using R version 3.4.0 to compare these outcomes of interest between the two groups. Fisher’s exact and Wilcoxon rank sum tests were used to compare the categorical and continuous variables respectively. Results: The HCV positive group was at a significantly higher risk of dose delays (100% vs. 33%, p = 0.01), dose changes (67% vs. 8%, p = 0.02), and hospitalization during chemotherapy (83% vs. 25%, p = 0.04) than their HCV matched controls. The risk of getting a dose delay due to hematotoxicity was significantly higher in the HCV positive group than the HCV negative group (83% vs. 8%, p = 0.003). The HCV positive patients took longer time to complete their treatment cycles than the HCV negative group. Conclusions: Chronic HCV infection in breast cancer patients receiving chemotherapy may be complicated by their active HCV infection. Treatment challenges due to dose changes, dose delays and hospitalizations were significantly more common when compared to controls. Chemotherapy delays and dose changes during breast cancer treatment has a negative consequence. In the era of curative treatment for HCV, future studies focused on the effect and treatment of concurrent HCV and breast cancer treatment is warranted.
Citation Format: Saptaparni Ghosh, Minghua L Chen, Janice Weinberg, Naomi Y Ko. Effects of hepatitis C virus infection on the safety of chemotherapy for breast cancer patients: A retrospective chart analysis [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P4-14-12.